Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients

[1]  Sebastian Bickelhaupt,et al.  Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T , 2018, Neuro-oncology.

[2]  Sebastian Bickelhaupt,et al.  Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients , 2018, Oncotarget.

[3]  Hye-Young Heo,et al.  Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics , 2018, European Radiology.

[4]  Guangtao Zhai,et al.  A Deep Learning-Based Radiomics Model for Prediction of Survival in Glioblastoma Multiforme , 2017, Scientific Reports.

[5]  P. V. van Zijl,et al.  Predicting IDH mutation status in grade II gliomas using amide proton transfer‐weighted (APTw) MRI , 2017, Magnetic resonance in medicine.

[6]  J. Boxerman,et al.  Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape , 2017, Journal of Neuro-Oncology.

[7]  Hany Soliman,et al.  Chemical exchange saturation transfer for predicting response to stereotactic radiosurgery in human brain metastasis , 2017, Magnetic resonance in medicine.

[8]  Peter Bachert,et al.  Simultaneous mapping of water shift and B1(WASABI)—Application to field‐Inhomogeneity correction of CEST MRI data , 2017, Magnetic resonance in medicine.

[9]  Jinyuan Zhou,et al.  Amide proton transfer imaging to discriminate between low- and high-grade gliomas: added value to apparent diffusion coefficient and relative cerebral blood volume , 2017, European Radiology.

[10]  Daniel Paech,et al.  Downfield‐NOE‐suppressed amide‐CEST‐MRI at 7 Tesla provides a unique contrast in human glioblastoma , 2017, Magnetic resonance in medicine.

[11]  H. Schlemmer,et al.  Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma. , 2016, Neuro-oncology.

[12]  C. Zimmer,et al.  Multiparametric MRI-based differentiation of WHO grade II/III glioma and WHO grade IV glioblastoma , 2016, Scientific Reports.

[13]  M. Götz,et al.  Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response , 2016, Clinical Cancer Research.

[14]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[15]  Hye-Young Heo,et al.  Quantitative assessment of amide proton transfer (APT) and nuclear overhauser enhancement (NOE) imaging with extrapolated semisolid magnetization transfer reference (EMR) signals: II. Comparison of three EMR models and application to human brain glioma at 3 Tesla , 2016, Magnetic resonance in medicine.

[16]  David Bonekamp,et al.  Association of overall survival in patients with newly diagnosed glioblastoma with contrast‐enhanced perfusion MRI: Comparison of intraindividually matched T1‐ and T2*‐based bolus techniques , 2015, Journal of magnetic resonance imaging : JMRI.

[17]  Peter Bachert,et al.  Signature of protein unfolding in chemical exchange saturation transfer imaging , 2015, NMR in biomedicine.

[18]  Benjamin Schmitt,et al.  Relaxation-compensated CEST-MRI of the human brain at 7T: Unbiased insight into NOE and amide signal changes in human glioblastoma , 2015, NeuroImage.

[19]  Daniel Paech,et al.  Correction of B1‐inhomogeneities for relaxation‐compensated CEST imaging at 7 T , 2015, NMR in biomedicine.

[20]  Daniel Paech,et al.  Nuclear Overhauser Enhancement Imaging of Glioblastoma at 7 Tesla: Region Specific Correlation with Apparent Diffusion Coefficient and Histology , 2015, PloS one.

[21]  Peter Bachert,et al.  A combined analytical solution for chemical exchange saturation transfer and semi‐solid magnetization transfer , 2015, NMR in biomedicine.

[22]  Tsutomu Okada,et al.  Grading glial tumors with amide proton transfer MR imaging: different analytical approaches , 2015, Journal of Neuro-Oncology.

[23]  Daniel Paech,et al.  Nuclear Overhauser Enhancement Mediated Chemical Exchange Saturation Transfer Imaging at 7 Tesla in Glioblastoma Patients , 2014, PloS one.

[24]  Dario Livio Longo,et al.  Chemical exchange saturation transfer (CEST): an efficient tool for detecting molecular information on proteins' behaviour. , 2014, The Analyst.

[25]  Jiadi Xu,et al.  Variable delay multi‐pulse train for fast chemical exchange saturation transfer and relayed‐nuclear overhauser enhancement MRI , 2014, Magnetic resonance in medicine.

[26]  Peter Bachert,et al.  Inverse Z‐spectrum analysis for spillover‐, MT‐, and T1‐corrected steady‐state pulsed CEST‐MRI – application to pH‐weighted MRI of acute stroke , 2014, NMR in biomedicine.

[27]  Kevin B. Kim.  PFS as a surrogate for overall survival in metastatic melanoma. , 2014, The Lancet. Oncology.

[28]  Koji Yamashita,et al.  Amide proton transfer imaging of adult diffuse gliomas: correlation with histopathological grades. , 2014, Neuro-oncology.

[29]  Alexander Radbruch,et al.  MR imaging of protein folding in vitro employing Nuclear‐Overhauser‐mediated saturation transfer , 2013, NMR in biomedicine.

[30]  Richard A. E. Edden,et al.  Nuclear Overhauser enhancement (NOE) imaging in the human brain at 7T , 2013, NeuroImage.

[31]  Klaus H. Maier-Hein,et al.  The Medical Imaging Interaction Toolkit: challenges and advances , 2013, International Journal of Computer Assisted Radiology and Surgery.

[32]  Tao Jin,et al.  MR imaging of the amide‐proton transfer effect and the pH‐insensitive nuclear overhauser effect at 9.4 T , 2013, Magnetic resonance in medicine.

[33]  Albert Lai,et al.  Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study , 2012, Journal of Neuro-Oncology.

[34]  T. Cloughesy,et al.  Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. , 2011, Neuro-oncology.

[35]  Thomas Benner,et al.  Early Experience of Translating pH-Weighted MRI to Image Human Subjects at 3 Tesla , 2010, Stroke.

[36]  Sally Freels,et al.  Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. , 2010, Neuro-oncology.

[37]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[39]  Jinyuan Zhou,et al.  Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging , 2008, Magnetic resonance in medicine.

[40]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[41]  R. Stupp,et al.  Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  Douglas C. Miller,et al.  Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.

[43]  Toshihiro Kumabe,et al.  Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. , 2006, Radiology.

[44]  C. Meyer,et al.  Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[46]  R. Gonzalez,et al.  MRI in treatment of adult gliomas. , 2005, The Lancet. Oncology.

[47]  Ying Lu,et al.  Survival analysis in patients with glioblastoma multiforme: Predictive value of choline‐to‐n‐acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume , 2004, Journal of magnetic resonance imaging : JMRI.

[48]  Jinyuan Zhou,et al.  Amide proton transfer (APT) contrast for imaging of brain tumors , 2003, Magnetic resonance in medicine.

[49]  Jinyuan Zhou,et al.  Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI , 2003, Nature Medicine.

[50]  M. Silvestrini,et al.  Diagnostic delay and prognosis in primary central nervous system lymphoma compared with glioblastoma multiforme , 2015, Neurological Sciences.